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Abstract
Background: As stavudine remains an important and widely prescribed drug in resource-limited settings, the
effect of a reduced dose of stavudine (from 40 mg to 30 mg) on outcomes of highly active antiretroviral therapy
(HAART) remains an important public health question.
Methods: We analyzed prospectively collected data from the Themba Lethu Clinic in Johannesburg, South Africa.
We assessed the relationship between stavudine dose and six- and/or 12-month outcomes of stavudine
substitution, failure to suppress viral load to below 400 copies/ml, development of peripheral neuropathy,
lipoatrophy and hyperlactatemia/lactic acidosis. Since individuals with a baseline weight of less than 60 kg were
expected to have received the same dose of stavudine throughout the study period, analysis was restricted to
individuals who weighed 60 kg or more at baseline. Data were analyzed using logistic regression.
Results: Between 1 April 2004 and 30 September 2009, 3910 patients were initiated on antiretroviral therapy (ART)
with a recorded stavudine dose and were included in the analysis. Of these, 2445 (62.5%) received a 40 mg
stavudine dose while 1565 (37.5%) received 30 mg. In multivariate analysis, patients receiving a 40 mg dose were
more likely to discontinue stavudine use (adjusted odds ratio, OR 1.71; 95% confidence limits, CI 1.13-2.57) than
those receiving 30 mg by 12 months on ART. Additionally, patients receiving 40 mg doses of stavudine were more
likely to report peripheral neuropathy (OR 3.12; 95% CI 1.86-5.25), lipoatrophy (OR 11.8; 95% CI 3.2-43.8) and
hyperlactatemia/lactic acidosis (OR 8.37; 95% CI 3.83-18.29) in the same time period. Failure to suppress HIV viral
load within 12 months of HAART initiation was somewhat more common among those given 40 mg doses (OR
1.62; 95% CI 0.88, 2.97) although this result lacked precision. Sensitivity analyses accounting for death and loss to
follow up generally supported these estimates.
Conclusions: Lower stavudine dosage is associated with fewer reports of several stavudine-associated adverse
events and also a lower risk of stavudine discontinuation within the first year on ART.
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Background
Stavudine (d4T) is a nucleoside analogue that has been
widely used as part of highly active antiretroviral therapy
(HAART). Despite being highly effective [1,2], use of
stavudine-based regimens has been eliminated from
resource-rich environments due to the poor side effects
profile and high rates of adverse events. In particular,
stavudine-containing regimens have been associated
with metabolic complications, such as dyslipidemias,
lipoatrophy and other mitochondrial toxicities, notably
peripheral neuropathy and lactic acidosis [3-14]. This
led the World Health Organization (WHO) to recom-
mend a lower maximum dose of stavudine for all adults
in 2007 [15], and in 2009, to recommend that it no
longer be used for initial treatment of HIV infection due
to serious side effects [16].
Other antiretroviral agents have been developed and
exhibit lower rates of toxicity even among stavudine-
* Correspondence: mmaskew@witshealth.co.za
1Clinical HIV Research Unit, Department of Medicine, Faculty of Health
Sciences, University of the Witwatersrand, Johannesburg, South Africa
Full list of author information is available at the end of the article
Maskew et al. Journal of the International AIDS Society 2012, 15:13
http://www.jiasociety.org/content/15/1/13
© 2012 Maskew et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.experienced individuals. These include improvement of
dyslipidaemia on tenofovir [17-19] and lipoatrophy on
abacavir [20]. A large placebo-controlled trial comparing
stavudine and tenofovir demonstrated reduced rates of
investigator-reported lipoatrophy among the tenofovir
arm, but no difference in mortality, grade 3 or 4 clinical
adverse events, rates of HIV RNA suppression or CD4
count increases between the treatment arms [21]. How-
ever, despite changes in country-level antiretroviral
guidelines recommending the use of these newer agents,
cost has precluded their widespread use in resource-lim-
ited settings [6,22]; therefore, more than half of indivi-
duals receiving antiretroviral therapy have stavudine as
part of their first-line regimens in low- and middle-
income countries [23]. Alternate strategies need to be
sought to reduce stavudine-associated morbidity in
these settings.
Stavudine has traditionally been prescribed in weight-
dependent doses: 30 mg for those weighing less than 60
kg, and 40 mg for those at or above 60 kg. However,
u s i n g3 0m go fs t a v u d i n em a yr e d u c ea d v e r s ee v e n t s
and toxicities without reducing efficacy regardless of
body weight. In addition to the studies noted, small-
scale randomized trials have suggested a trend towards
a decrease in plasma lipids and improvements in periph-
eral wasting with lower-dose stavudine [17,24]. How-
ever, in order to be a useful strategy, the optimal dose
of stavudine that limits drug-induced toxicity while
maintaining virologic potency needs to be investigated
in large populations in resource-limited settings where
the clinical and economic pressure to continue stavu-
dine use is high.
We evaluated the effectiveness and tolerance of a dose
of 30 mg versus 40 mg stavudine as part of HAART
regimens in an HIV-infected population receiving
HAART.
Methods
Study site and data collection
Themba Lethu Clinic is an urban antiretroviral rollout
site based at Helen Joseph Hospital, a public hospital in
Johannesburg, South Africa. Since the national rollout of
antiretroviral drugs in 2004, the clinic has enrolled more
than 23,000 HIV-infected adults and currently provides
free antiretroviral therapy to more than 16,000 of these
patients according to the South African national Depart-
ment of Health’s guidelines on rollout of antiretroviral
therapy [25]. Standard first-line therapy in South Africa
at the time of this analysis consisted of stavudine, lami-
vudine and efavirenz (or nevirapine). Treatment was
initiated at CD4 counts of 200 cells/mm
3 or less or a
clinical WHO stage III/IV [26].
Clinical, demographic and laboratory data is collected
prospectively. Patient information is recorded
electronically by attending nurses and clinicians during
clinical visits, while a team of trained data capturers
conduct quality assurance checks. Prior to initiating
HAART, all patients receive adherence counselling and
have a staging baseline CD4 count taken. Patients return
monthly to pick up medication and are scheduled for
clinical assessment by a doctor at one, two and four
months after initiation of HAART or as clinically indi-
cated. After four months, patients return for clinical vis-
its every six months or as clinically indicated. Initial
assessment of treatment success (as determined by CD4
count response and suppression of HIV viral load) is
measured at the four-month visit and six monthly
thereafter.
We analyzed previously collected data for all HAART-
naïve adult patients initiating stavudine-containing
HAART between 1 April 2004 and 30 September 2009,
and followed up until 1 April 2010, allowing for a mini-
mum of six months of follow up for each subject.
Women who were pregnant at initiation were excluded
as they are initiated on HAART at higher CD4 counts,
have different HAART regimens [25] and have variable
CD4 counts (due to the hemodilution effect of preg-
nancy) compared with the general population. With few
exceptions, individuals weighing less than 60 kg at
HAART initiation received a 30 mg dose of stavudine
throughout follow up. Thus, we studied only individuals
with baseline weights of 60 kg or more, as these were
the only subjects who saw a variation of dose in the
study period (see the next section, Exposure).
Exposure
The exposure was defined as the dose of stavudine pre-
scribed at baseline. Until the end of 2007, stavudine dos-
ing was weight-based in South Africa, with Department
of Health guidelines prescribing 30 mg doses for those
weighing less than 60 kg and 40 mg doses for those
weighing 60 kg or more. From October 2007, a univer-
sal 30 mg dose was introduced and 40 mg tablets of sta-
vudine were withdrawn from the clinic. Thus, we
limited the study to those with baseline weights of 60 kg
or more, and the dose received was defined by calendar
date (40 mg in the pre-change period, 30 mg in the
post-change period).
Dosing was essentially concordant with protocol: a
validation review of 50 records of randomly selected
subjects with baseline weights of 60 kg or more before
January 2008 yielded a high concordance (> 95%) of
recorded dose with protocol. To ensure precise defini-
tions, we instituted a “wash-out” period from July 2007
until March 2008. Individuals initiated onto treatment
during this period were excluded from the study. We
conducted an intent-to-treat analysis by assuming that
dose did not change in the first 12 months of follow up.
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We considered five outcomes at up to two time points.
These outcomes were: 1) virologic failure; 2) disconti-
nuation of stavudine; 3) peripheral neuropathy evaluated
at both six and 12 months; 4) lipoatrophy and 5) hyper-
lactatemia/lactic acidosis, (the last two were evaluated at
12 months only due to very few cases occurring in the
first six months). Virologic failure was defined as failure
to suppress virus to < 400 copies/ml by six or 12
months; individuals without a viral load measurement in
the first six or 12 months were excluded from analysis
of this last outcome. A patient was considered to have
experienced peripheral neuropathy, lipoatrophy or
hyperlactatemia/lactic acidosis if, during the study per-
iod, a clinical diagnosis was recorded on the patient
record by the attending physician. The procedures for
detecting and managing hyperlactatemia and lactic
acidosis remained constant throughout the study period.
This included clinical screening and formal laboratory
testing for lactate levels. All individuals with raised lac-
tate levels were referred to the Helen Joseph Hospital
for further investigation and management, including
arterial blood gas status, where appropriate.
Statistical methods
Characteristics of patients by dose of stavudine were
described using simple descriptive statistics. Effects of
the exposure on the outcomes (as we have listed) were
calculated using logistic regression to estimate odds
ratios. Since the incidence of most outcomes were low
(≤ 10%), those odds ratios generally approximated risk
ratios. All analyses controlled for confounding by base-
line weight, height, age, gender, ethnicity, employment
status, haemoglobin, CD4 count, WHO stage, tuberculo-
sis status, reported baseline peripheral neuropathy,
calendar date and whether clinical care was free at base-
line. We controlled for both age and weight using rela-
tively unrestrictive four-knot restricted cubic splines.
We performed two sensitivity analyses to account for
potential selection bias by death or loss to follow up in
the six-month analyses. We first implemented inverse
probability of censoring weights [27] and, second,
included all death and loss-to-follow-up events as evi-
dence of a poor outcome (e.g., stavudine substitution,
incident peripheral neuropathy, or virologic failure).
Use of Themba Lethu Clinic data was approved by the
Human Research Ethics Committee of the University of
the Witwatersrand. Approval for analysis of de-identified
data was also granted by the Boston University and
Duke University Institutional Review Boards.
Results
There were 3910 patients who met the inclusion criteria.
Of these, 63.5% (n = 2445) initiated HAART prior to 1
July 2007 and received 40 mg stavudine, while the
remaining 37% (n = 1465) initiated HAART after 1
March 2008 and thus had 30 mg stavudine doses (Table
1). Of these patients, 42% (n = 1645) were male; median
(interquartile range, IQR) baseline weight was 67 kg
(63-75); and median (IQR) age was 37 years (32-43).
Seven percent (n = 256) of patients either died (n =
137) or were lost to follow up (n = 119) within the first
six months on HAART.
Only 71% (n = 2785) of patients had a viral load taken
within six months and 80% (n = 3139) within 12
months of initiating HAART. At six and 12 months,
missing data was similar between the 30 mg and 40 mg
dosing groups: 29.2% vs. 28.5% at six months, and 19.9%
vs. 21.1% at 12 months. At six months, 1037 had a viral
load measurement in the 30 mg group, and 1748 in the
40 mg group. Of these, a total of 177 (6%) failed to sup-
press virus: 44 (4.2%) in the 30 mg group and 133
(7.6%) in the 40 mg group by 12 months (Table 2). At
12 months, 1171 had a viral load measurement in the
30 mg group, and 1968 in the 40 mg group. Of these, a
total of 266 (8.5%) failed to suppress virus: 58 (5.0%) in
the 30 mg group and 208 (10.6%) in the 40 mg group
by 12 months (Table 2). Failure to suppress within six
months of HAART initiation was more common among
those given 40 mg than those given 30 mg in crude ana-
lyses (OR = 1.86; 95% CI 1.31-2.64). In adjusted ana-
lyses, failure to suppress was somewhat more common
among those given 40 mg than those given 30 mg at six
(OR 1.69; 95% CI 0.81-3.52) and 12 months (OR 1.62;
95% CI 0.88-2.97), although neither result was statisti-
cally significant. Neither CD4 count nor other indicators
of disease status were independently predictive of virolo-
gic failure at either six or 12 months.
Table 1 Characteristics of 3910 individuals initiating
HAART at Themba Lethu Clinical by baseline dose of
stavudine
Baseline characteristic Dose of stavudine
40 mg
n = 2445
30 mg
n = 1465
Weight† 67.0 (62.8-74.0) 68.1 (63.6-75.6)
Age† 37 (32-43) 38 (33-44)
Male gender 1017(41.6) 628 (42.9)
African ethnicity 2,348 (96.0) 1,416 (96.7)
Employed 1,130 (46.2) 855 (58.4)
Tuberculosis 364 (14.9) 155 (10.6)
Haemoglobin (low) 823 (35.0) 433 (29.8)
WHO stage III or IV 956 (39.1) 356 (24.3)
CD4 count (cells/mm
3)† 97 (39-163) 137 (66-192)
Efavirenz-based HAART 2203 (90.1) 1296 (88.5)
Nevirapine-based HAART 193 (7.9) 116 (7.9)
All figures expressed as count (%) unless noted. † Expressed as median
(interquartile range)
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in HAART regimen within six months of HAART
initiation, and a total of 19% (n = 752) did so by 12
months (Table 2). In both cases, a clear majority of
these involved a switch to a non-stavudine-containing
HAART regimen (n = 195 and n = 571, respectively).
Looking at the 12-month stavudine substitution out-
come, of the 571 non-stavudine-containing regimens,
16% (n = 92) contained TDF; a substantially greater
percentage of those were among people receiving a 30
mg dose (39%, compared with 8% in the 40 mg dose
group).
Crude analyses are shown in Table 2; in adjusted ana-
lysis, patients started on a 40 mg dose were no more
likely to discontinue stavudine within six months com-
pared with those started on a 30 mg dose (OR 0.87; 95%
CI 0.45-1.71), but at 12 months, a 40 mg dose was asso-
ciated with increased risk (OR 1.71; 95% CI1.13-2.57).
Limiting the analysis to only those who received a non-
TDF-based regimen gave an adjusted odds ratio of 2.22
(95% CI 1.42-3.48). Among the 571 initial drug regimens
in which stavudine was substituted within 12 months,
the leading cause for substitution was peripheral neuro-
pathy (n = 156), and a total of 63% were for specifically
toxicity-related reasons. Toxicity was more common as
a listed reason for stavudine substitution among those
receiving a 40 mg dose (76%) than among those receiv-
ing a 30 mg dose (30%).
About 6% (n = 251) of patients reported peripheral
neuropathy within six months of HAART initiation and
10% (n = 398) by 12 months (Table 2). At both time
periods and after adjustment for confounding, the risk
for peripheral neuropathy was substantially elevated
among those who received a 40 mg dose of stavudine at
baseline compared with those receiving 30 mg; the
adjusted odds ratios were similar at six and 12 months
(3.17 and 3.12, respectively; see Table 2).
Lipoatrophy was reported in less than 2% (n = 81) of
subjects by 12 months, and only four of those subjects
had initiated HAART on a 30 mg dose (Table 2). The
adjusted odds ratio comparing a 40 mg dose with a 30
mg dose for this outcome was 11.8 (95% CI 3.2-43.8).
The combined outcome of hyperlactatemia and lactic
acidosis was reported in 5% (n = 194) of subjects, and
only 15 of those subjects had initiated HAART on a 30
mg dose (Table 2). The adjusted odds ratio for this
combined lactate outcome was 8.37 (95% CI 3.83-18.29).
In the 30 mg group, all of these events were hyperlacta-
temia. In the 40 mg group, there were 60% (108 cases)
hyperlactatemia, and 40% (71 cases) lactic acidosis.
Under a Poisson distribution, the upper 95% confidence
limit for incidence of lactic acidosis among subjects with
40 mg dose is approximately 3/1465 or 0.002.
In sensitivity analysis of the six-month outcomes,
implementation of inverse probability of censoring
weights had almost no effect on point estimates (a less
Table 2 Crude and adjusted odds ratios
† comparing 40 mg (n = 2445) and 30 mg (n = 1465) dose of stavudine on
outcomes
Outcome Exposure N (%) Crude OR
†
(95% CI)
Adjusted OR
††
(95% CI)
Six months
Virologic failure 30 mg 44 (4.2%) 1 1
40 mg 133 (7.6%) 1.86 (1.31-2.64) 1.69 (0.81-3.52)
Stavudine discontinuation 30 mg 60 (4.1%) 1 1
40 mg 135 (5.5%) 1.37 (1.00-1.87) 0.87 (0.45-1.71)
Peripheral neuropathy 30 mg 31 (2.1%) 1 1
40 mg 220 (9.0%) 4.57 (3.12-6.70) 3.17 (1.71-5.90)
Twelve months
Virologic failure 30 mg 58 (5.0%) 1 1
40 mg 208 (10.6%) 2.27 (1.68-3.06) 1.62 (0.88-2.97)
Stavudine discontinuation 30 mg 158 (10.8%) 1 1
40 mg 413 (16.9%) 1.68 (1.38-2.05) 1.71 (1.13-2.57)
Peripheral neuropathy 30 mg 41 (2.8%) 1 1
40 mg 357 (14.6%) 5.94 (4.27-8.26) 3.12 (1.86-5.25)
Lipoatrophy 30 mg 4 (0.3%) 1 1
40 mg 81 (3.3%) 12.5 (4.6-34.2) 11.8 (3.2-43.8)
Hyperlactemia/lactic acidosis 30 mg 15 (1.0%) 1 1
40 mg 179 (7.3%) 7.64 (4.49-12.99) 8.37 (3.83-18.29)
†OR = Odds ratios estimated using logistic regression models
††Estimates adjusted for baseline weight, height, age, gender, ethnicity, employment status, haemoglobin, CD4 count, WHO stage, tuberculosis status, reported
baseline peripheral neuropathy, calendar date, and whether clinical care was free at baseline
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censoring (that is, dead or lost to follow up) as a nega-
tive outcome resulted in a qualitatively different result
only for the effect of dose on peripheral neuropathy; the
odds ratio for the effect of a 40 mg dose on incident
peripheral neuropathy in this analysis was 2.15 (95% CI
1.38-3.35). Additionally, we note that limiting the six-
month adjusted analyses to those who were least likely
(due to timing) to have switched stavudine doses within
those first six months of treatment slightly increased the
effect of dose on risk of failure to 1.97 (95% CI 0.91-
4.25) and did not meaningfully affect other six-month
outcomes.
We also noted that patients not receiving EFV or NVP
were largely on Kaletra (lopinavir-ritonavir). In further
sensitivity analysis, the exclusion of these individuals
reduced precision slightly, but did not meaningfully
affect point estimates. The estimate for virologic failure
at 12 months moved from 1.62 (95% CI 0.88-2.97) to
1.64 (0.89-3.03) when limited to only those with NPV-
or EFV-based regimens. Similarly, the estimate for sta-
vudine discontinuation went from 1.71 (1.13-2.57) to
1.73 (1.14-2.61) and for peripheral neuropathy from 3.12
(1.86-5.25) to 3.14 (1.86-5.30).
Discussion
Despite a well-described toxicity profile and several
alternate drug options, stavudine remains widely pre-
scribed in developing countries [28,29]. Recent estimates
suggest that 60% of individuals receiving antiretroviral
therapy have stavudine as part of their first-line regi-
mens in low- and middle- income countries [23]. Stavu-
dine use has largely ceased in resource-rich settings and
WHO guidelines no longer recommend its use [16].
Probably due to this, little attention is currently being
paid to questions that are relevant to countries still
using this drug, such as determining the optimal dose
and the effect of a reduced dose on HAART outcomes
[29]. In resource-limited settings, the cost and virologic
potency of stavudine, coupled with the limited need for
intensive laboratory-based monitoring has meant that
stavudine remains an important drug in the rapid scale
up of antiretroviral therapy in countries with the great-
est need.
Over the past few years, several stavudine-dosing
schemes have been used: a universal 40 mg dose [30];
weight-based dosing [26,31]; and a universal 30 mg dose
[16]. Each of these dosing schemes has potential advan-
tages and disadvantages: higher doses may be more
effective at controlling viral load, but have potentially
poorer adherence, while lower doses may reduce side
effects, but be less effective at suppressing virus. In this
study, we sought to address the relative advantages and
disadvantages of stavudine dose.
Stavudine use has been shown to result in frequent
(up to 30%) discontinuation of drug use due to multiple
adverse events, including peripheral neuropathy, dyslipi-
demias, lipoatrophy and mitochondrial toxicity
[1,3-9,14,22,30-34]. There are, however, few studies
directly examining the effect of stavudine dose on treat-
ment outcomes [7,17,24,35,36] particularly from
resource-limited settings where stavudine is still widely
used [8,37,38]. Our study is the first that we are aware
of to examine these effects among a large urban cohort
of HIV-infected patients receiving stavudine in this
setting.
Compared with a 30 mg dose of stavudine, we found
that a 40 mg dose was associated with a high risk of
several stavudine-associated adverse events within the
first year of treatment. These events included peripheral
neuropathy (OR 3.12; 95% CI 1.86-5.25), lipoatrophy
(OR 11.8; 95% CI 3.2-43.8) and hyperlactatemia/lactic
acidosis (OR 8.37; 95% CI 3.83-18.29). Those receiving
the higher dose were also more likely to discontinue sta-
vudine use within the first 12 months on ART (OR
1.71;1 95% CI.13-2.57). Since the 30 mg dose was given
later in time, when drugs like tenofovir were more
widely available, it is reasonable to be concerned that
these results are being driven by the desirability or
acceptability of these alternate drugs. However, limiting
the analysis to only those who received a non-tenofovir-
based regimen gave an adjusted odds ratio of 2.22 (95%
CI 1.42-3.48), a stronger effect than the main result for
12-month odds of stavudine substitution, suggesting
that this was not the case.
We found no evidence of impaired viral suppression
with a 30 mg dose of stavudine. If anything, the esti-
mates suggest the 40 mg dose may be associated with a
small increased risk of failure to suppress virus within
12 months (OR 1.62; 95% CI 0.88-2.97) though the
imprecise nature of this estimate does not allow us to
infer the association with confidence. If, however, a 40
mg dose does actually increase risk of initial failure to
suppress virus, then it is possibly due to increased fre-
quency of peripheral neuropathy and other adverse
events interfering with adherence [6]. This would mean,
moreover, that a 30 mg dose would not sacrifice effec-
tiveness for safety. Rather, it suggests that increasing
safety may actually increase effectiveness. In fact, in sev-
eral of the randomized studies comparing 40 mg and 30
mg stavudine doses, individuals with low body weight
received an even further reduced dose of 20 mg of sta-
vudine. Among those with lower body weight, the 20
mg dose could improve safety further without compro-
mising tolerability and effective virologic suppression
[35,36].
Newer drugs like tenofovir have become available, and
while it appears to be better tolerated than stavudine in
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trophy in particular [2,8,21], this has been demonstrated
largely in comparison to the higher 40 mg dose of sta-
vudine and may not hold true for the lower dose. Data
from a randomized trial in Spain comparing a 40 mg
stavudine dose with a 30 mg dose or switch to tenofovir
demonstrated that both strategies improved peripheral
fat and lipid parameters, but only switching to tenofovir
was associated with significant reversal of lipoatrophy
[16]. Additionally, rates of discontinuation of stavudine
(even at the 30 mg dose) are substantially higher than
on tenofovir [39].
The 30 mg dose was associated with lower prevalence
of lipoatrophy compared with those who had received
both 30 mg and 40 mg dosages and individuals receiving
AZT in Cameroon [8], although an Asian cohort
showed higher discontinuation rates for people taking
ZDV versus d4T [40]. A review of nucleoside-switch
trials found modest improvement in peripheral wasting
after discontinuation of stavudine [41]. Additionally, use
of tenofovir can be complicated by toxicity and side
effects, including renal insufficiency, osteoporosis and
osteopenia. While the risk of renal insufficiency on
tenofovir appears to be low and related to pre-existing
renal disease [42,43], the limited availability of screening
for creatinine clearance and the fact that the cost of this
drug is still currently more than five times that of stavu-
dine [44] are important considerations for limiting the
use of tenofovir in resource-limited settings.
Our results should be interpreted in light of the
potential limitations of the study. First, we studied the
effect of stavudine dose only among those with weights
of 60 kg or more, and, therefore, these findings may not
apply to those with a lower weight at treatment initia-
tion. Second, we performed this analysis on an intent-
to-treat basis regarding both weight and dose. While
weight and dose may both change after treatment initia-
tion, this was not taken into consideration. However, all
outcomes were considered at, or within 12 months of,
treatment initiation, and we do not presume to extrapo-
late these findings beyond this time period.
Third, we were unable to specifically control for the
effects of secular trends in care provision and manage-
ment of adverse events. However, we do note that the
largest change in clinical practice in this period was in
October 2006 when any fee for clinical care was
stopped: while this has a strong effect on loss-to-follow-
up rates (data not shown), it had relatively little effect
on odds ratios reported here and was controlled for in
this analysis, and we believe it unlikely that other secular
trends were so confounding as to render these results
uninterpretable. Last, the effect of death and loss to fol-
low up were not considered in the primary analysis.
While this may have introduced selection bias into the
estimates presented, sensitivity analyses showed little
difference in estimates when censoring was counted as a
negative outcome.
Conclusions
Our findings from this large cohort offer further evi-
dence that a lower dosage of 30 mg stavudine appears
safe and effective within the first year of treatment, and
can be implemented in settings where alternate drug
options are unavailable. Additional evidence from
resource-limited settings is needed to determine
w h e t h e rar o u t i n e2 0m gd o s eo fs t a v u d i n ea sp a r to fa
HAART regimen is of benefit for patients with low body
weights. Lower stavudine dosage is associated with fewer
reports of several stavudine-associated adverse events
and also a lower risk of stavudine discontinuation within
the first year on ART.
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